Request for Proposal
Status: RFP is Open

Human Tumor Samples with Many Frameshift Mutations or Their Analysis Data

Request Number
Due Date
Feb 6
Program Manager

Joint/contract research, licensing, sample and data supply

Start considering the source of samples or data within half a year

Details to be negotiated based on proposals

How to  Apply
  • Click "Respond", complete the form to the extent possible, and submit along with other attachment files available. 
  • After creating your account for NineSights, your draft will be automatically saved and you can resume later from "Control Center". Please note you do not submit confidential information at this process.
  • This request for proposals in PDF format is available here.
If you have any questions or request, please feel free to contact us at:

RFP Title


Human Tumor Samples with Many Frameshift Mutations or Their Analysis Data
RFP Description

NineSigma, representing Daiichi Sankyo Company, Limited ( ('Client'), seeks either human tumor samples with many frameshift mutations or whole exome sequencing analysis (WES) / RNA sequencing (RNA-Seq) analysis data of these samples.

The Client desires to analyze the expression of frameshift mutation-derived mRNAs and the expression of multiple genes that are the targets of their drugs by RNA-Seq using human tumor samples or analysis data held by the proposer. The challenge is, however, for the client to obtain data from other than public database. The client wants to accelerate drug development by combining samples and data from other companies and organizations. Therefore, the client decided to this public offering.

Key Success Criteria

Required sample/data

Either one of the following samples is required:

  1. Human tumor sample with many frameshift mutations for WES/RNA-Seq analysis
  2. WES and RNA-Seq data of human tumor samples with many frameshift mutations 

Requirements for samples or data

Aforementioned samples or data must meet the following requirements:

  • Samples or their data to which informed consent was given for WES and RNA-Seq
  • Samples or their data that show the results of treatment with immune checkpoint inhibitor
  • Many (i.e., 5 or more) frameshift mutations have been identified in each sample
  • Although there are no designations of cancer types or races, it is desirable that minimum 10 cases from a single cancer type are available
  • When providing samples, frozen samples are more preferable
Approaches not of Interest

Approaches Not of Interest

The following approaches are not of interest:

  • Analytical data based on the public database such as TCGA (The Cancer Genome Atlas)
Items to be Submitted

Notes on Response

Proposal shall have clear points and should not include confidential information. Supplemental files may be submitted in addition to the proposal. 

Response evaluation

The client will evaluate all responses with the following criteria:

  • Details of proposal and proposer profile
  • Feasibility of achieving target specifications
  • Economic potential of concept
  • Related experiences

Anticipated Project Process

After the submission due date, the client will review all submitted proposals. NineSigma will send the review results to each proposer 6-8 weeks after the due date. The client possibly asks clarifying questions before selecting the most suitable candidates for collaboration. The client will select best candidates through evaluations. During the selection process, the client may execute NDA with selected respondents, seek further information disclosure, and discuss specific development targets or potential opportunities.

The client will execute necessary agreements with the selected respondents and move to the advanced development phase. Specifics of any collaboration will be determined through consultation with the concerned parties.

Preferred Collaboration Types
Area of Interest